AppLovin stock rises as Wall Street resets targets — what traders are watching next
13 January 2026
1 min read

AppLovin stock rises as Wall Street resets targets — what traders are watching next

New York, January 13, 2026, 11:12 AM (ET) — Market open

AppLovin shares rose roughly 0.5% Tuesday, recovering after a volatile start as investors digested new price targets from brokers on the ad-tech firm.

Timing is crucial. Since the start of the year, AppLovin has behaved like a momentum play, and even slight shifts in sell-side sentiment can sway the stock when positioning is tight and expectations run high.

At 11:12 a.m. ET, the stock changed hands at $662.24, having fluctuated from a low of $643.00 to a high of $666.57. The wider market edged lower, with the S&P 500 ETF slipping around 0.2% and the Nasdaq 100 ETF also down about 0.2%.

Morgan Stanley bumped up its price target on AppLovin to $800 from $750, maintaining an “overweight” rating. Meanwhile, Goldman Sachs shaved its target slightly to $710 from $720 but stuck with a “neutral” stance, according to MT Newswires reports carried by MarketScreener. (A price target estimates where a stock might trade; “overweight” suggests expectations to beat peers.) MarketScreener data shows 27 analysts cover AppLovin, with an average target near $742 and a consensus “buy.” (MarketScreener)

The stock closed Monday at $658.65, marking a 1.69% gain for the day, according to historical pricing data. (Investing)

AppLovin provides software that enables advertisers to purchase and track ads while helping app publishers monetize their users. The company is pivoting more toward advertising technology after agreeing to sell its mobile games studio portfolio to Tripledot Studios for roughly $800 million in cash and stock. This deal puts more focus on its marketing platform. (Reuters)

Still, the stock isn’t without headline risk. AppLovin has been under the microscope for its data-collection methods. Back in October, Reuters reported the U.S. SEC was investigating the company’s practices, citing sources familiar with the matter. It’s unclear how far along that review is. Any regulatory action, a shift in platform rules, or renewed interest from short sellers could quickly sour sentiment in a stock priced for growth. (Reuters)

AppLovin is set to drop its quarterly numbers next. The company plans to unveil its fourth-quarter and full-year 2025 results on Feb. 11, after U.S. markets shut. A management webcast will follow at 5:00 p.m. ET. (Applovin)

Stock Market Today

  • ABBV inks drug pricing deal with Trump, joins PD-1xVEGF bandwagon
    January 13, 2026, 2:32 PM EST. AbbVie said it signed a U.S. pricing agreement with the Trump administration to cut list prices to match those in comparable developed markets, backing the MFN proposal. The deal includes a three-year exemption from import tariffs on pharmaceutical ingredients if AbbVie expands U.S. manufacturing, and a pledge to invest $100 billion over the next decade in domestic R&D and capital. The government says 16 of 17 large drugmakers have reached similar accords; Regeneron remains in talks. In a separate release, AbbVie agreed to an exclusive license with RemeGen for its PD-1xVEGF bispecific, RC148. AbbVie will pay an upfront $650 million and up to $4.95 billion in milestones, plus royalties, for rights outside Greater China. RC148 is in phase II in China, with potential in NSCLC and CRC. Competitors include Summit, BioNTech/Bristol Myers, Merck and Pfizer pursuing PD-1/VEGF programs.
UiPath stock slides after CEO Daniel Dines sells shares — what PATH investors watch next
Previous Story

UiPath stock slides after CEO Daniel Dines sells shares — what PATH investors watch next

TTM Technologies stock surges nearly 20% as TTMI draws fresh attention at Needham Growth Conference
Next Story

TTM Technologies stock surges nearly 20% as TTMI draws fresh attention at Needham Growth Conference

Go toTop